US 11,672,811 B2
Materials and methods for suppressing and/or treating bone related diseases and symptoms
Teresita M. Bellido, Zionsville, IN (US); G. David Roodman, Indianapolis, IN (US); Jesus Delgado-Calle, Indianapolis, IN (US); Robert K. Boeckman, Honeoye Falles, NY (US); and Frank H. Ebetino, Venice, FL (US)
Assigned to Indiana University Research and Technology Corporation, Indianapolis, IN (US); University of Rochester, Rochester, NY (US); and The United States of America as Represented by the Department of Veteranas Affairs, Washington, DC (US)
Appl. No. 16/635,769
Filed by Indiana University Research and Technology Corporation, Indianapolis, IN (US); University of Rochester, Rochester, NY (US); and The United States of America As Represented by the Department of Veterans Affairs Office of General, Washington, DC (US)
PCT Filed Aug. 2, 2018, PCT No. PCT/US2018/045037
§ 371(c)(1), (2) Date Jan. 31, 2020,
PCT Pub. No. WO2019/028270, PCT Pub. Date Feb. 7, 2019.
Claims priority of provisional application 62/540,396, filed on Aug. 2, 2017.
Prior Publication US 2020/0368259 A1, Nov. 26, 2020
Int. Cl. A61K 31/664 (2006.01); A61P 35/00 (2006.01); A61K 38/29 (2006.01); A61K 45/06 (2006.01); C07F 9/38 (2006.01)
CPC A61K 31/664 (2013.01) [A61K 38/29 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07F 9/3886 (2013.01)] 5 Claims
 
1. A compound, comprising:
A-Y—B,
wherein:
A is

OG Complex Work Unit Chemistry
and X is selected from the group consisting of: H and

OG Complex Work Unit Chemistry
Y is a linker of formula NR1;
R′ is H, CH3, alkyl, halogen, CF3, CN, OH, OCH3, or O-alkyl;
wherein R1 is NR2R3, NR2S(═O)2R3 or R2OR3;
R2 and R3 are independently selected from H, C1-C10 alkyl, C1-C10 alkoxy, C6H5OR4, and wherein R2 and R3 are not both H,
R4 is C1-C10 alkyl, C1-C10 alkoxy, carbonyl, or amide; and
B is at least one bisphosphonate optionally substituted with OH, halogen, CH3, NH2,
or a pharmaceutically acceptable salt thereof.